home edit2 whole TSD November 2002 PDF format - OEHHA

Potency Equivalency Factors (PEF) for PAHs and derivatives. It has a cancer potency of 11.5 (mg/kgday)
-1 and inhalation unit risk of 1.1 × 10 3 (µg/m 3 ) -1 . For the potency equivalency scheme, it was
assigned a PEF of 1.
2. Dibenz[a,h,]anthracene. An expedited potency of 4.1 (mg/kg-day) -1 was derived using the
linearized multistage model with the only dose-response data set available - a drinking water study
(Snell and Stewart, 1962) which reported alveolar carcinomas of the lung in male DBA/2 mice due to
dibenz[a,h]anthracene (incidence = 14/21 at 28.3 mg/kg-day versus 0/25 in controls). An inhalation
unit risk can be obtained from a potency under the assumption that the chemicals are equally absorbed
and are equally potent by oral and inhalation routes and that a 70 kg person inhales 20 cubic meters of
air per day. When the potency in units of (mg/kg-day) -1 is divided by 3500 (70 kg * 1000 µg/mg/20
m 3 ), an inhalation unit risk is obtained in units of (µg/m 3 ) -1 .
3. 7,12-Dimethylbenzanthracene. An expedited potency of 250 (mg/kg-day) -1 was derived. The only
study listed in the Gold et al. cancer potency (TD50) database (Gold et al., 1984; 1986; 1987; 1989;
1990) is the feeding study by Chourolinkov et al. (1967) in female albino mice. Significant increases in
malignant angioendotheliomas of the mesenteric intestine and papillomas of the forestomach were
observed in animals treated with 0.39 mg/kg-day of 7,12-dimethylbenzanthracene. Cancer potency is
based on mesenteric intestine angioendothelioma incidence (incidence = 49/75 versus 0/40 in controls).
4. 3-Methylcholanthrene. An expedited potency of 22 (mg/kg-day) -1 was derived. Results of 3
studies in male Long Evans rats, one study in an unspecified strain of female rats, and 10 studies in
female Wistar rats were included in the Gold et al. database. All studies in female rats found highly
significant increases in tumors of the mammary gland. The cancer potency for 3-methylcholanthrene
was taken as the geometric mean of cancer potencies estimated from 9 of the 10 studies in female rats
(Shay et al., 1962; Gruenstein et al., 1964; Shay et al., 1961). The upper bound on potency could
not be estimated from one of the studies by Shay et al. (1961), because 100% of the treated animals
developed mammary gland tumors.
5. 5-Nitroacenaphthene. An expedited potency of 0.13 (mg/kg-day) -1 was derived based on the
combined incidence of benign and malignant tumors of the ear canal in female rats. Usable studies were
feeding studies by Takemura et al. (1974) in female Syrian golden hamsters and by the National Cancer
Institute (1978) in male and female B6C3F 1 mice and F344 rats. The compound 5-nitroacenaphthene
induced increases in tumor incidences at multiple sites in rats and female mice. Rats were the most
sensitive species; the sensitivity of males were similar to that of females.
6. Benzo[b]fluoranthene. Benzo[b]fluoranthene was assigned a PEF of 0.1. Clement Associates
(1988) applied both a two stage model and the multistage model to various data sets for several PAHs.
The two models generally gave similar results for relative potency. In order to verify the results,
OEHHA staff (OEHHA, 1993) used GLOBAL86 to fit the multistage model to the tumor data used by
Clement Associates and obtained relative cancer potencies similar to those obtained by Clement
Associates. Clement Associates (1988) used the mouse skin carcinogenesis data obtained by Habs et
al. (1980) and the intrapulmonary administration to rats by Deutsch-Wenzel et al. (1983) to estimate a
110